Polarean Imaging (POLX)

Sector:

Health Care

Index:

FTSE AIM All-Share

 4.30p
   
  • Change Today:
      0.000p
  • 52 Week High: 30.75p
  • 52 Week Low: 3.90p
  • Currency: UK Pounds
  • Shares Issued: 215.85m
  • Volume: 2,223,270
  • Market Cap: £9.28m

Polarean receives FDA approval for drug device combination product

By Iain Gilbert

Date: Wednesday 28 Dec 2022

LONDON (ShareCast) - (Sharecast News) - Medical imaging technology group Polarean said on Wednesday that its drug device combination product has been granted approval by the US Food and Drug Administration.
Polarean stated the FDA had approved its XENOVIEW asset, prepared from the Xenon Xe 129 Gas Blend, for use with magnetic resonance imaging for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.

The AIM-listed group also announced that two 510(k) devices were cleared by the FDA that will further support a successful launch of the technology into the clinical marketplace - XENOVIEW VDP and XENOVIEW 3.0T Chest Coil.

Chief executive Richard Hullihen said: "FDA approval represents [an] achievement of a major milestone for Polarean's technology. This was only possible in close collaboration with multiple research clinicians and scientists globally, who we thank for their tireless and enthusiastic work.

"Approval of XENOVIEW represents a major step forward in modern respiratory imaging and we are proud to have pioneered this exciting new technology for clinical use. The commercial team at Polarean is prepared to rapidly launch XENOVIEW for clinical application."

As of 0820 GMT, Polarean shares had shot up 42.35% to 69.75p.





Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

POLX Market Data

Currency UK Pounds
Share Price 4.30p
Change Today 0.000p
% Change 0.00 %
52 Week High 30.75p
52 Week Low 3.90p
Volume 2,223,270
Shares Issued 215.85m
Market Cap £9.28m

POLX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
Market averageMarket averageMarket averageMarket averageMarket average
75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average
Price Trend
Market averageMarket averageMarket averageMarket averageMarket average
89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average
Income Not Available
Growth
Market averageMarket averageMarket averageMarket averageMarket average
83.33% below the sector average83.33% below the sector average83.33% below the sector average83.33% below the sector average83.33% below the sector average

POLX Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
14:47 1,000,000 @ 4.25p
16:12 246,409 @ 4.24p
15:51 1,049 @ 4.24p
15:44 6,635 @ 4.24p
15:16 100,000 @ 4.40p

POLX Key Personnel

CFO Charles Osborne
CEO Christopher von Jako

Top of Page